Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 88

Results For "Formulation"

944 News Found

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


SPI Pharma partners Azelis Americas
Supply Chain | August 07, 2021

SPI Pharma partners Azelis Americas

In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace


India Initiates anti dumping probe against import of ATS-8 from China
Policy | August 04, 2021

India Initiates anti dumping probe against import of ATS-8 from China

Arch Pharma Labs has filed the application


Drug exports grow on the back of govt support
Policy | August 03, 2021

Drug exports grow on the back of govt support

Drug formulations and biologics make impressive gains


NPPA monitors and caps prices of essential drugs: Mandaviya
Policy | August 03, 2021

NPPA monitors and caps prices of essential drugs: Mandaviya

NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22


Bharat Biotech gets WHO prequalification for ROTAVAC 5D
Biotech | August 02, 2021

Bharat Biotech gets WHO prequalification for ROTAVAC 5D

WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO